Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Only 12 Evaluable Patients at 450 days 67% CR !!!!!!

<< Previous

Bullboard Posts

Next >>

Comment by O12009on Apr 26, 2023 7:18pm

122 Views

Post# 35415867

RE:Only 12 Evaluable Patients at 450 days 67% CR !!!!!!

So they haven't applied to the FDA?

I was trying to do the math to figure out 12 patients. If you take away the 3 from phase1 , the 12 under treated and the one who died, from 29 that will leave 13? So I'm guessing that is not it, unless there was another under treated.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand